Synergistic Anti-Cancer Effects of ERB-041 and Genistein through Estrogen Receptor Suppression-Mediated PI3K/AKT Pathway Downregulation in Canine Mammary Gland Tumor Cells

• Published in: International journal of molecular sciences Vol. 25; no. 5; p. 2466
• Main Authors: Yoo, Min-Jae, Jang, Ye-Ji, Park, Sang-Youel, Choi, Ja-Wun, Seol, Jae-Won
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 20.02.2024; MDPI
• Subjects: Animals; Apoptosis; Breast cancer; Cancer; Cancer therapies; canine-mammary-gland tumors; Cell cycle; Cell death; Cell growth; Chemotherapy; Dogs; Down-Regulation; ERB-041; Estrogen; estrogen receptor; Estrogen Receptor alpha - metabolism; Estrogen Receptor beta - genetics; Estrogens; Estrogens - metabolism; Female; genistein; Genistein - pharmacology; Humans; Isoflavones; Kinases; Mammary Glands, Human - metabolism; Medical prognosis; Morphology; Oxazoles; Phenols; Phosphatases; Phosphatidylinositol 3-Kinases - metabolism; PI3K/AKT pathway; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Receptors, Estrogen - metabolism; Soybean; Tumors; Germany; genistein; estrogen receptor; canine-mammary-gland tumors; ERB-041; PI3K/AKT pathway
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25052466

Canine-mammary-gland tumors (CMTs) are prevalent in female dogs, with approximately 50% of them being malignant and often presenting as inoperable owing to their size or metastasis. Owing to poor outcomes, effective alternatives to conventional chemotherapy for humans are necessary. Two estrogen receptors, estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which act in opposition to each other, are involved, and CMT growth involves ERα through the phosphoinositide 3-kinases (PI3K)/AKT pathway. In this study, we aimed to identify the synergistic anti-cancer effects of ERB-041, an ERβ agonist, and genistein, an isoflavonoid from soybeans known to have ERβ-specific pseudo-estrogenic actions, on CMT-U27 and CF41.Mg CMT cell lines. ERB-041 and genistein synergistically inhibited cell proliferation and increased the number of annexin V-positive cells in both cell lines. Furthermore, we observed a synergistic increase in the Bax/Bcl-2 ratio and cleaved caspase-3 expression. Additionally, cell-cycle arrest occurred through the synergistic regulation of cyclin D1 and cyclin-dependent kinase 4 (CDK4). We also found a synergistic decrease in the expression of ERα, and the expression of proteins involved in the PI3K/AKT pathway, including p-PI3K, phosphatase and tensin homolog (PTEN), AKT, and mechanistic target of rapamycin (mTOR). In conclusion, ERB-041 and genistein exhibited a synergistic anticancer effect on CMTs, suggesting that cotreatment with ERB-041 and genistein is a promising treatment for CMTs.